Stocks · News reference

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20

Jul 27, 2026, 1:47 PMBenzinga Newsdesk

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $20.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 27, 2026, 1:47 PM
Checked: Jul 27, 2026, 1:47 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 25, 2026, 11:33 AMBenzinga Newsdesk
Zevra Therapeutics To Present Two Posters Featuring Long-Term Real-World Data On MIPLYFFA For Treatment Of Niemann-Pick Disease Type C At SSIEM Annual Symposium
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two
Read original at benzinga
ZVRA
BenzingaAug 20, 2026, 10:24 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target
Read original at benzinga
ZVRA
BenzingaAug 7, 2026, 5:10 PMBenzinga Newsdesk
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.
Read original at benzinga
ZVRA
BenzingaAug 6, 2026, 3:05 PMBenzinga Newsdesk
Zevra Therapeutics shares are trading higher after Citizens raised its price target on the stock from $25 to $28.
Read original at benzinga
ZVRA